Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 Debt-to-EBITDA is 3.27 as of Sep. 2025, which is 10% below its 10-year median of 3.65. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 683 Drug Manufacturers companies, Sai Parenteral's ranks worse than 85.65% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sai Parenteral's's Debt-to-EBITDA or its related term are showing as below:
NSE:SAIPARENT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.59 Med: 3.65 Max: 6.54
Current: 6.54
During the past 3 years, the highest Debt-to-EBITDA Ratio of Sai Parenteral's was 6.54. The lowest was 3.59. And the median was 3.65.
NSE:SAIPARENT's Debt-to-EBITDA is ranked worse than 85.65% of 683
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs NSE:SAIPARENT: 6.54
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sai Parenteral's Debt-to-EBITDA Related Terms
Sai Parenteral's Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Debt-to-EBITDA Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
Debt-to-EBITDA
3.65
3.59
3.75
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Debt-to-EBITDA
N/A
N/A
N/A
3.27
NSE:SAIPARENT vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Sep. 2025) EBITDA data.
Sai Parenteral's (NSE:SAIPARENT) has a Debt-to-EBITDA of 3.27 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sai Parenteral's. This is 10% below median its historical median of 3.65. Over the past decade, Sai Parenteral's' Debt-to-EBITDA has ranged from 3.59 to 6.54. According to the industry distribution chart, Sai Parenteral's ranks #585 out of 683 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Sai Parenteral's' Debt-to-EBITDA too high?
Sai Parenteral's' current Debt-to-EBITDA of 3.27 is 10% below median its 10-year median of 3.65. Over the past 10 years, this metric has ranged from a low of 3.59 to a high of 6.54. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Sai Parenteral's' value of 3.27 is 100.6% above this industry median. Based on the distribution chart, Sai Parenteral's ranks #585 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #585 out of 683 companies for Debt-to-EBITDA. This places Sai Parenteral's in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Sai Parenteral's' value of 3.27 is 100.6% above this benchmark. Historically, Sai Parenteral's' own Debt-to-EBITDA has ranged from 3.59 to 6.54 over the past decade. While the company's 10-year median is 3.65 vs. the industry median of 1.63, Sai Parenteral's has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current Debt-to-EBITDA of 3.27 is 100.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sai Parenteral's. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current Debt-to-EBITDA is 3.27, which is 10% below median its own 10-year median of 3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Debt-to-EBITDA of 3.27. The current Debt-to-EBITDA is 3.27, which is 10% below median its 10-year median of 3.65 and 100.6% above the Drug Manufacturers industry median of 1.63. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Debt-to-EBITDA is 3.27 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
